Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBS314 in relapsed/refractory multiple myeloma (Phase I/II)
CTR20240206Phase 2Active
- Sponsor
- Kactus Biosystems
- Start
- Feb 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MBS314 in multiple myeloma (MM), sponsored by Kactus Biosystems. Started Feb 2024; status: active.
02
Drugs
MBS314
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20240206.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240206.